Comparison of the Risk of Cancer Between Patients With Type 2 Diabetes Exposed to Dapagliflozin and Those Exposed to Other Antidiabetic Treatments
Phase of Trial: Phase IV
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Dapagliflozin (Primary) ; Antihyperglycaemics; Insulin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors AstraZeneca
- 08 Mar 2017 Planned End Date changed from 1 Apr 2024 to 30 Apr 2024.
- 08 Mar 2017 Planned primary completion date changed from 1 Apr 2024 to 30 Apr 2024.
- 05 Apr 2016 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.